A year after distressed buyout, what’s become of Bluebird Bio? CEO David Meek says the company, now called Genetix, is leading in sickle cell gene therapy

https://www.statnews.com/2026/07/02/genetix-david-meek-bluebird-bio-turnaround-effort/ By Jason MastJuly 2, 2026 General Assignment Reporter